Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Clinical Research and Equipment Industry Analysis

UpdatedApr 20, 2026
DataAggregated Company Financials
Companies7
  • 7D4.6%
  • 3M0.2%
  • 1Y4.3%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has risen 5.8%, driven by gains from every company within the industry. This takes the industry's 12 month performance to a gain of 4.3%. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 20 Apr 2026CHF 51.1bCHF 10.1bCHF 1.1b35.3x44.7x5x
Wed, 18 Mar 2026CHF 45.8bCHF 10.1bCHF 1.1b30.8x40x4.5x
Fri, 13 Feb 2026CHF 47.5bCHF 10.1bCHF 1.3b30.9x37.3x4.7x
Sun, 11 Jan 2026CHF 51.4bCHF 10.6bCHF 1.1b32.7x46.7x4.8x
Tue, 09 Dec 2025CHF 49.5bCHF 10.7bCHF 1.1b28.2x45x4.6x
Thu, 06 Nov 2025CHF 48.8bCHF 10.6bCHF 1.1b28.5x44.4x4.6x
Sat, 04 Oct 2025CHF 51.1bCHF 10.6bCHF 1.1b31.7x46.5x4.8x
Mon, 01 Sep 2025CHF 53.0bCHF 10.6bCHF 1.1b34.4x48.1x5x
Wed, 30 Jul 2025CHF 55.1bCHF 10.7bCHF 1.1b35x47.9x5.2x
Fri, 27 Jun 2025CHF 52.5bCHF 10.1bCHF 1.0b33.5x50.5x5.2x
Sun, 25 May 2025CHF 51.8bCHF 10.1bCHF 1.0b30.8x49.9x5.1x
Tue, 22 Apr 2025CHF 49.4bCHF 10.1bCHF 1.0b28.1x48.2x4.9x
Thu, 20 Mar 2025CHF 53.5bCHF 10.1bCHF 1.0b33.4x52.6x5.3x
Sat, 15 Feb 2025CHF 57.1bCHF 10.1bCHF 1.0b36.4x56.7x5.7x
Mon, 13 Jan 2025CHF 54.2bCHF 10.2bCHF 943.4m35.3x57.4x5.3x
Wed, 11 Dec 2024CHF 52.5bCHF 10.2bCHF 943.8m38.5x55.6x5.1x
Fri, 08 Nov 2024CHF 55.7bCHF 10.2bCHF 943.4m43.5x59.1x5.5x
Sun, 06 Oct 2024CHF 54.4bCHF 10.2bCHF 943.3m41.8x57.6x5.3x
Tue, 03 Sep 2024CHF 57.1bCHF 10.2bCHF 937.0m44.9x60.9x5.6x
Thu, 01 Aug 2024CHF 59.9bCHF 10.2bCHF 923.6m45.6x64.9x5.8x
Sat, 29 Jun 2024CHF 52.3bCHF 10.3bCHF 1.0b44.8x52.2x5.1x
Mon, 27 May 2024CHF 54.7bCHF 10.3bCHF 1.0b45.2x54.6x5.3x
Wed, 24 Apr 2024CHF 55.2bCHF 10.3bCHF 1.0b44x55.1x5.4x
Fri, 22 Mar 2024CHF 56.8bCHF 10.2bCHF 1.0b46.1x56.6x5.5x
Sun, 18 Feb 2024CHF 49.9bCHF 10.2bCHF 1.0b45.9x49x4.9x
Tue, 16 Jan 2024CHF 42.5bCHF 9.8bCHF 1.5b31.9x28.4x4.3x
Thu, 14 Dec 2023CHF 39.1bCHF 9.8bCHF 1.5b30.2x26.2x4x
Sat, 11 Nov 2023CHF 39.6bCHF 9.8bCHF 1.5b27.5x26.5x4x
Mon, 09 Oct 2023CHF 47.0bCHF 9.8bCHF 1.5b31.9x31.5x4.8x
Wed, 06 Sep 2023CHF 53.3bCHF 9.8bCHF 1.5b36.9x35.7x5.5x
Fri, 04 Aug 2023CHF 52.4bCHF 9.8bCHF 1.5b35.2x33.9x5.4x
Sun, 02 Jul 2023CHF 55.6bCHF 9.7bCHF 1.6b36.2x34x5.7x
Tue, 30 May 2023CHF 60.0bCHF 9.7bCHF 1.6b37.6x36.7x6.2x
Thu, 27 Apr 2023CHF 58.3bCHF 9.7bCHF 1.6b41.2x35.7x6x
Price to Earnings Ratio

35.7x


Total Market Cap: CHF 58.3bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Clinical Research and Equipment Industry Price to Earnings3Y Average 46.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.1x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 12% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Swiss Clinical Research and Equipment compare with similar industries?

CH Market2.01%
Healthcare0.66%
Life Sciences4.58%
Clinical Research and Equipment4.58%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 543.405.1%
+CHF 1.8b		0.8%PE41.8x
SFZN Siegfried HoldingCHF 84.055.4%
+CHF 188.4m		-5.5%PE21.8x
SKAN SKAN GroupCHF 49.3510.5%
+CHF 105.7m		-21.4%PE68.2x
TECN Tecan GroupCHF 138.002.6%
+CHF 43.9m		-2.8%PS2x
BANB Bachem HoldingCHF 70.150.5%
+CHF 26.2m		48.2%PE35.3x

Latest News

SFZN
CHF 84.05
Siegfried Holding
7D
5.4%
1Y
-5.5%
XLS
CHF 22.90
Xlife Sciences
7D
14.5%
1Y
14.5%
TECN
CHF 138.00
Tecan Group
7D
2.6%
1Y
-2.8%

TECN: AI Lab Collaboration And Execution Discipline Will Support Future Earnings

The analyst price target for Tecan Group has shifted slightly to around CHF 167, with recent CHF 1 and CHF 17 target reductions from different firms. These moves have led analysts to fine tune assumptions on discount rate, revenue growth, profit margin and future P/E, without changing the overall valuation picture in a major way.
BANB
CHF 70.15
Bachem Holding
7D
0.5%
1Y
48.2%

BANB: Future Upside Will Depend On Executing Profit Margin Assumptions

Narrative Update Bachem Holding's updated analyst price target now reflects a modest recalibration in assumptions, with recent CHF 5, CHF 80, and CHF 32 target increases cited by analysts who point to slightly higher profit margin expectations and a small adjustment to the assumed P/E multiple as key drivers. Analyst Commentary Recent research updates on Bachem Holding have leaned constructive, with bullish analysts adjusting their price targets upward and citing a mix of valuation and execution factors.
LONN
CHF 543.40
Lonza Group
7D
5.1%
1Y
0.8%
SKAN
CHF 49.35
SKAN Group
7D
10.5%
1Y
-21.4%
PPGN
CHF 36.25
PolyPeptide Group
7D
1.0%
1Y
117.1%